CFON 026
Alternative Names: CFON-026Latest Information Update: 19 Dec 2024
Price :
$50 *
At a glance
- Originator Crossfire Oncology
- Class Antineoplastics
- Mechanism of Action Agammaglobulinaemia tyrosine kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Solid tumours
Most Recent Events
- 23 Oct 2024 Pharmacodynamics data from preclinical studies in Cancer presented at the 36th EORTC-NCI-AACR Symposium on molecular targets and cancer therapeutics (EORTC-NCI-AACR-2024)
- 27 Jun 2024 Crossfire Oncology plans a first in human trial for Cancer in second half of 2025 (Crossfire Oncology pipeline, June 2024)
- 05 Apr 2024 Preclinical trials in Solid tumours in Netherlands (unspecified route) before April 2024